Home > Healthcare > Medical Devices > Therapeutic Devices > Artificial Pancreas Device Systems (APDS) Market

Artificial Pancreas Device Systems (APDS) Market Size

  • Report ID: GMI6912
  • Published Date: Oct 2023
  • Report Format: PDF

Artificial Pancreas Device Systems Market Size

Artificial Pancreas Device Systems Market size was valued at USD 331 million in 2022 and is estimated to account for USD 757.5 million by 2032. Increasing number of people suffering from chronic conditions such as obesity resulting in occurrence of diabetes will act as a primary factor for driving market demand.

 

Artificial Pancreas Device Systems Market

To understand key trends  
Download Free Sample
 

For instance, according to official statistics, over 80% of people suffering from Type 2 diabetes are obese. An artificial pancreas device system (APDS) is a medical device designed for individuals with diabetes. It combines a continuous glucose monitor (CGM), the market of which is projected to reach USD 21.4 billion by 2032, an insulin pump, and a computer algorithm to automatically regulate blood glucose levels. The system continuously monitors glucose levels and adjusts insulin delivery in real-time, mimicking the function of healthy pancreas.

 

Factors such as sedentary lifestyle, unhealthy diet, and an aging population base contribute to the rising incidence of both type 1 and type 2 diabetes. For instance, as per the report of International Diabetes Federation's Diabetes Atlas 10th edition, the number of adults (aged 20-79) suffering from diabetes is anticipated to surge to 783.2 million by 2045. These statistics underscore the escalating worldwide burden of diabetes and its significant impact on public health. Therefore, there is an urgent need for effective and efficient methods to manage the disease. APDS offers a promising solution by automating glycemic control, helping patients maintain stable blood glucose levels. Furthermore, prominent medical device companies are heavily investing in APDS technology leading to the development of more advanced, user-friendly systems, improving performance, patient outcomes, and market adoption, ultimately driving market expansion.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global artificial pancreas device systems industry was valued at USD 331 million in 2022 and is estimated to account for USD 757.5 million by 2032.

The threshold suspends device systems segment garnered USD 175 million in 2022 and will grow through 2032 attributed to the advanced safety features of these devices.

U.S. artificial pancreas device systems industry accounted for USD 122 million in 2022 and is predicted to witness substantial growth through 2032 due to the surge in the diabetes population base in the country.

Medtronic Plc, Johnson & Johnson Services Inc., Bigfoot Biomedical, Tandem Diabetes Care, Inc., Pancreum, Inc., TypeZero Technologies, LLC, Beta Bionics, Insulet Corporation, Defymed, Inreda Diabetic, and Diabeloop.

Artificial Pancreas Device Systems Market Scope

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2022
  • Companies covered: 11
  • Tables & Figures: 218
  • Countries covered: 22
  • Pages: 175
 Download Free Sample